ARTICLE | Finance
uniQure completes comeback
How Dutch gene therapy play uniQure re-remerged on public markets - in U.S.
February 10, 2014 8:00 AM UTC
Dutch gene therapy play uniQure N.V. (NASDAQ:QURE) is back on the public markets after a two-year hiatus. The company has taken advantage of renewed interest in gene therapy as well as the willingness of U.S. investors to invest in European companies.
uniQure's Glybera alipogene tiparvovec is the first gene therapy approved outside of China. Partner Chiesi Farmaceutici S.p.A. plans to launch Glybera to treat LPL deficiency in Europe in the first half...